AGN only deals with primary brain injury has nothing to do with secondary, Mycardial infarction and cardiovascular protection and reduction of sudden cardiac arrest. Only drug in that market. Imagine the amount of billions of dollars big pharma going to give for the only drug in that space. Aptoll is your example for the amount of billions they gave them on phase 2a. No competition in this space for NYR and why management and major share holders soaked you up trading for a pip lol.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.025(10.6%) |
Mkt cap ! $54.83M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 26.5¢ | 23.5¢ | $352.7K | 1.440M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3600 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 4499 | 1 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |